✦ LIBER ✦

Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia

✍ Scribed by Eric Tse; Anskar Y. H. Leung; Joycelyn Sim; Harold K. K. Lee; Herman S. Y. Liu; Sze-Fai Yip; Yok-Lam Kwong

Book ID: 105989859
Publisher: Springer
Year: 2011
Tongue: English
Weight: 98 KB
Volume: 90
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-011-1223-2

No coin nor oath required. For personal study only.

✦ Synopsis

Clofarabine (40 mg/m^2^/day × 5) and high-dose cytosine arabinoside (Ara-C, 1–2 g/m^2^/day × 5) were used in 10 men and 11 women, at a median age of 45 (22–62) years, with refractory (N = 4) and relapsed (N = 17) acute myeloid leukaemia, after a median of 3 (2–5) prior regimens. Grade 4 myelosuppression was observed in all cases, with two patients dying of bacterial sepsis. Nine patients achieved a complete remission. Disease status, number of prior therapies, and cytogenetic aberrations were not associated with the outcome. However, remission was only achieved with Ara-C at 2 g/m^2^/day and not 1 g/m^2^/day (9/15 versus 0/4, P = 0.03).

📜 SIMILAR VOLUMES

Treatment of relapsed and refractory acu

Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide

✍ Martin Gore; Ray Powles; Anil Lakhani; Sarah Milan; Jennifer Maitland; Glen Goss 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 425 KB

A total of 65 patients under the age of 55 with acute leukaemia received high-dose cytosine arabinoside (Ara-C) in combination with high-dose etoposide without an anthracycline. Complete remission rates for patients with relapsed or refractory acute myelogenous leukaemia (AML) were 15/25 (60%) and 1

Fludarabine and cytosine arabinoside in

Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia

✍ Samer Suki; Hagop Kantarjian; Varsha Gandhi; Elihu Estey; Susan O'Brien; Milosla 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 571 KB

## Background: The objectives of the study were to evaluate the antileukemic efficacy and toxicity profiles of the combination of fludarabine and intermediate-dose cytosine arabinoside (ara-c) in refractory or relapsed adult acute lymphocytic leukemia (all). patients and methods. thirty adults with

Clofarabine with high dose cytarabine an

Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia

✍ Pamela S. Becker; Hagop M. Kantarjian; Frederick R. Appelbaum; Stephen H. Peters 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB

Mitoxantrone and high-dose cytosine arab

Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia

✍ Hagop M. Kantarjian; Ronald L. Walters; Michael J. Keating; Elihu H. Estey; SUSA 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 447 KB 👁 2 views

Twenty-five adult patients with refractory acute lymphocytic leukemia received salvage therapy with mitoxantrone 5 mg/m2 intravenously over 1 hour daily for 5 days and cytosine arabinoside 3 g/m2 intravenously over 2 hours every 12 hours for six doses. Overall, nine patients (36%) achieved complete

High-dose VP-16 with intermediate-dose c

High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia

✍ Hon Y. Chan; Frederick J. Meyers; Jerry P. Lewis 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 147 KB

Clofarabine in the treatment of poor ris

Clofarabine in the treatment of poor risk acute myeloid leukaemia

✍ Janusz Krawczyk; Naeem Ansar; Ronan Swords; Tracy Murphy; Barry MacDonagh; Teres 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

## Abstract Clofarabine is a second generation nucleoside analogue. It inhibits DNA repair and activates the mitochondrial apoptotic pathway leading to cell death. __In vitro__ clofarabine has demonstrated synergy with daunorubicin and Ara‐C and in phase II clinical trials has shown promising activ